Literature DB >> 20454876

Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.

Jarrod W Collier1, Rakhi B Shah, Abhay Gupta, Vilayat Sayeed, Muhammad J Habib, Mansoor A Khan.   

Abstract

Stability of formulations over shelf-life is critical for having a quality product. Choice of excipients, manufacturing process, storage conditions, and packaging can either mitigate or enhance the degradation of the active pharmaceutical ingredient (API), affecting potency and/or stability. The purpose was to investigate the influence of processing and formulation factors on stability of levothyroxine (API). The API was stored at long-term (25 degrees C/60%RH), accelerated (40 degrees C/75%RH), and low-humidity (25 degrees C/0%RH and 40 degrees C/0%RH) conditions for 28 days. Effect of moisture loss was evaluated by drying it (room temperature, N(2)) and placed at 25 degrees C/0%RH and 40 degrees C/0%RH. The API was incubated with various excipients (based on package insert of marketed tablets) in either 1:1, 1:10, or 1:100 ratios with 5% moisture at 60 degrees C. Commonly used ratios for excipients were used. The equilibrium sorption data was collected on the API and excipients. The API was stable in solid state for the study duration under all conditions for both forms (potency between 90% and 110%). Excipients effect on stability varied and crospovidone, povidone, and sodium laurel sulfate (SLS) caused significant API degradation where deiodination and deamination occurred. Moisture sorption values were different across excipients. Crospovidone and povidone were hygroscopic whereas SLS showed deliquescence at high RH. The transient formulation procedures where temperature might go up or humidity might go down would not have major impact on the API stability. Excipients influence stability and if possible, those three should either be avoided or used in minimum quantity which could provide more stable tablet formulations with minimum potency loss throughout its shelf-life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454876      PMCID: PMC2902299          DOI: 10.1208/s12249-010-9434-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  12 in total

Review 1.  Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes.

Authors:  K R Morris; U J Griesser; C J Eckhardt; J G Stowell
Journal:  Adv Drug Deliv Rev       Date:  2001-05-16       Impact factor: 15.470

2.  Selection of solid dosage form composition through drug-excipient compatibility testing.

Authors:  A T Serajuddin; A B Thakur; R N Ghoshal; M G Fakes; S A Ranadive; K R Morris; S A Varia
Journal:  J Pharm Sci       Date:  1999-07       Impact factor: 3.534

3.  Excipient compatibility study of Hypericum perforatum extract (St. John's wort) using similarity metrics to track phytochemical profile changes.

Authors:  Susan H Kopelman; Larry L Augsburger
Journal:  Int J Pharm       Date:  2002-04-26       Impact factor: 5.875

4.  Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection.

Authors:  A G Kazemifard; D E Moore; A Aghazadeh
Journal:  J Pharm Biomed Anal       Date:  2001-07       Impact factor: 3.935

5.  Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation.

Authors:  L Gu; R G Strickley; L H Chi; Z T Chowhan
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

6.  Kinetics of degradation of levothyroxine in aqueous solution and in solid state.

Authors:  C M Won
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

7.  Thermal inactivation of L-thyroxin.

Authors:  J Wortsman; D C Papadimitriou; M Borges; C L Defesche
Journal:  Clin Chem       Date:  1989-01       Impact factor: 8.327

8.  Polymorphism in anhydrous theophylline--implications on the dissolution rate of theophylline tablets.

Authors:  N V Phadnis; R Suryanarayanan
Journal:  J Pharm Sci       Date:  1997-11       Impact factor: 3.534

9.  Effect of excipients on the stability of levothyroxine sodium tablets.

Authors:  V Das Gupta; C Odom; C Bethea; J Plattenburg
Journal:  J Clin Pharm Ther       Date:  1990-10       Impact factor: 2.512

10.  Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients.

Authors:  R B Shah; A Bryant; J Collier; M J Habib; M A Khan
Journal:  Int J Pharm       Date:  2008-04-20       Impact factor: 5.875

View more
  7 in total

Review 1.  Polymeric nucleic acid carriers: current issues and novel design approaches.

Authors:  Han Chang Kang; Kang Moo Huh; You Han Bae
Journal:  J Control Release       Date:  2012-07-04       Impact factor: 9.776

2.  Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery.

Authors:  Deepa Mishra; Han Chang Kang; You Han Bae
Journal:  Biomaterials       Date:  2011-02-26       Impact factor: 12.479

3.  Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.

Authors:  Wiriyaporn Sirikun; Jittima Chatchawalsaisin; Narueporn Sutanthavibul
Journal:  AAPS PharmSciTech       Date:  2015-07-24       Impact factor: 3.246

4.  Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium.

Authors:  Rakhi B Shah; Jarrod S Collier; Vilayat A Sayeed; Arthur Bryant; Muhammad J Habib; Mansoor A Khan
Journal:  AAPS PharmSciTech       Date:  2010-08-26       Impact factor: 3.246

5.  Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies.

Authors:  Wei Xu; Garth Boehm; Qiang Zheng
Journal:  Acta Pharm Sin B       Date:  2015-12-17       Impact factor: 11.413

Review 6.  Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.

Authors:  Salvatore Benvenga; Allan Carlé
Journal:  Adv Ther       Date:  2019-09-04       Impact factor: 3.845

7.  Stability and Compatibility Studies of Levothyroxine Sodium in Solid Binary Systems-Instrumental Screening.

Authors:  Ionuț Ledeți; Mirabela Romanescu; Denisa Cîrcioban; Adriana Ledeți; Gabriela Vlase; Titus Vlase; Oana Suciu; Marius Murariu; Sorin Olariu; Petru Matusz; Valentina Buda; Doina Piciu
Journal:  Pharmaceutics       Date:  2020-01-10       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.